CLINICAL TRIALS PROFILE FOR ACT-541468
✉ Email this page to a colleague
Clinical Trials for ACT-541468
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02526888 ↗ | Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects | Completed | Actelion | Phase 1 | The main objective of this study is to investigate whether repeated administration of a cardiac medication (diltiazem) can affect the pharmacokinetics (i.e., amount and time of presence in the blood) of ACT-541468 |
| NCT02526888 ↗ | Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects | Completed | Idorsia Pharmaceuticals Ltd. | Phase 1 | The main objective of this study is to investigate whether repeated administration of a cardiac medication (diltiazem) can affect the pharmacokinetics (i.e., amount and time of presence in the blood) of ACT-541468 |
| NCT02571855 ↗ | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects | Completed | Actelion | Phase 1 | The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of ACT-541468 following multiple ascending doses in healthy adults and following single ascending doses in healthy elderly subjects when administered in the morning. The safety, PK and PD of ACT-541468 will also be assessed after repeated evening administration of a selected dose in both healthy adults and elderly. |
| NCT02571855 ↗ | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects | Completed | Idorsia Pharmaceuticals Ltd. | Phase 1 | The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of ACT-541468 following multiple ascending doses in healthy adults and following single ascending doses in healthy elderly subjects when administered in the morning. The safety, PK and PD of ACT-541468 will also be assessed after repeated evening administration of a selected dose in both healthy adults and elderly. |
| NCT02839200 ↗ | Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder | Completed | Actelion | Phase 2 | This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG. |
| NCT02839200 ↗ | Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder | Completed | Idorsia Pharmaceuticals Ltd. | Phase 2 | This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG. |
| NCT02841709 ↗ | Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder | Completed | Actelion | Phase 2 | This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for ACT-541468
Condition Name
Clinical Trial Locations for ACT-541468
Trials by Country
Clinical Trial Progress for ACT-541468
Clinical Trial Phase
Clinical Trial Sponsors for ACT-541468
Sponsor Name
